Showing posts with label Biomarkers Industry. Show all posts
Showing posts with label Biomarkers Industry. Show all posts

Analyzing the Impact of Biomarkers Industry Mergers and Acquisitions on Market Dynamics

Biomarkers Industry Data Book - Cardiac Biomarkers, Cancer Biomarkers, Non-alcoholic Steatohepatitis Biomarkers, Neurological Biomarkers Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030

The global Biomarkers Industry was valued at USD 41.62 billion in 2021 and is anticipated to increase at a significant CAGR of 14.2% from 2022 to 2030.

Grand View Research’s biomarkers industry data book is a collection of market sizing & forecasts insights, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analyses studies. Within the purview of the database, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research. The following data points will be included in the final product offering in four reports and one sector report overview.

Access the Global Biomarkers Industry Data Book, 2023 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking, macro-environmental analyses, and regulatory & technological framework studies

Cardiac Biomarkers Market Growth & Trends

The global cardiac biomarkers market size is expected to reach USD 47.88 billion by 2030, expanding at a CAGR of 14.7% from 2023 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of acute coronary syndrome (ACS), along with advancements in biomarker technologies, is expected to propel market growth. The rising awareness regarding early diagnosis and prognosis of cardiac diseases is expected to further drive the market.

According to the NCBI, in 2021, in the U.S., over 15.5 million people were affected by coronary heart disease. Chest pain is one of the most common reasons for emergency department visits. Heart disease is one of the major causes of death in the U.S. and it is estimated that a person has a heart attack every 41 seconds. Cardiac biomarkers play a significant role in ACS diagnosis and facilitate faster treatment decision-making, thereby making them crucial.

The improving adoption of biomarkers in risk stratification and diagnosis of the acute coronary syndrome is impelling the demand. An unhealthy lifestyle is driving the prevalence of acute coronary syndrome and myocardial infarction. The increasing adoption of PoC diagnostics is driving segment innovation, making use of cardiac markers easier. The paradigm shift in the adoption of cardiac biomarkers in hospitals and PoC settings can be attributed to the recent developments in assays pertaining to the sensitivity of cardiac troponin I and cardiac troponin T.

Cardiac Biomarkers Market Share, by End use, 2021 (%)

Order your copy of the Free Sample of “Biomarkers Industry Data Book - Cardiac Biomarkers, Cancer Biomarkers, Non-alcoholic Steatohepatitis Biomarkers, Neurological Biomarkers Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

Non-alcoholic Steatohepatitis Biomarkers Market Growth & Trends

The global non-alcoholic steatohepatitis biomarkers market size is expected to reach USD 5.4 billion by 2030, registering a CAGR of 23.6% during the forecast period, according to a new report by Grand View Research, Inc. The growth of the Non-alcoholic Steatohepatitis (NASH) biomarkers market is attributed to rising prevalence of chronic diseases and rising demand for providing novel diagnostic tools. Nonalcoholic Fatty Liver Disease (NAFLD) is more prevalent in people with specific diseases, such as obesity, and diseases that may be linked to obesity, including type 2 diabetes. One-third to two-thirds of people with type 2 diabetes are projected to have NAFLD.

According to April 2021 study by NIH, up to 75% of overweight individuals and more than 90% of individuals with extreme obesity have NAFLD. An increasing obese population and unhealthy food habits are creating a favorable environment for the development of liver disease. Therefore, the rising prevalence of chronic liver disease is expected to fuel the demand for NASH biomarkers. The ongoing research activities in this sector are likely to sustain the market growth.

The primary factor pertaining to growth is the increasing incidence of chronic liver illnesses like nonalcoholic steatohepatitis and the need to develop ways for their early detection and diagnosis. The market for non-alcoholic steatohepatitis biomarkers has enormous growth potential despite the lack of a single reliable non-invasive procedure to diagnose NAFLD. Another growth factor is the increasing demand for non-invasive diagnosis methods as other diagnostic procedures available are intrusive and expensive, thus they are not suitable for patients.

Go through the table of content of Biomarkers Industry Data Book to get a better understanding of the Coverage & Scope of the study

Competitive Landscape

Key players operating in the Biomarkers industry are:

  • F. Hoffmann-La Roche Ltd.
  • Abbott
  • Epigenomics AG.
  • General Electric
  • Johnson and Johnson Services, Inc.

Check out more Industry Data Books, published by Grand View Research

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com/sector-reports-list
Follow Us: LinkedIn | Twitter

Biomarkers Industry: Expansion, Mergers and Acquisitions Details

Biomarkers Industry Data Book - Cardiac Biomarkers, Cancer Biomarkers, Non-alcoholic Steatohepatitis Biomarkers, Neurological Biomarkers Market Size, Share, Trends Analysis, and Segment Forecasts, 2023 - 2030

The global Biomarkers Industry was valued at USD 41.62 billion in 2021 and is anticipated to increase at a significant CAGR of 14.2% from 2022 to 2030.

Grand View Research’s biomarkers industry data book is a collection of market sizing & forecasts insights, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analyses studies. Within the purview of the database, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research. The following data points will be included in the final product offering in four reports and one sector report overview.

Cardiac Biomarkers Market Insights

The global cardiac biomarkers market size was valued at USD 13.98 billion in 2021 and is anticipated to grow at a compound annual growth rate (CAGR) of 14.7% from 2022 to 2030. Cardiac biomarkers are witnessing growth owing to factors such as the high prevalence of acute coronary syndrome, technological advancements in cardiac biomarkers, rising demand for point-of-care (POC) cardiac testing kits, and high specificity in detecting cardiac diseases, especially myocardial infarction.

The enhanced usage of cardiac biomarkers in SARS-CoV-2 patients to minimize the risk of cardiac diseases further drives the demand. For instance, according to National Center for Biotechnology Information (NCBI) in 2021, biomarkers for cardiac injuries were elevated in complicated cases of COVID-19 patients and were directly associated with adverse disease outcomes. Thus, cardiac biomarkers enabled the disease management of severely ill patients.

Moreover, cardiac test kits contain an array of combination tests that detect the presence of biomarkers, facilitating the easier diagnosis of cardiac diseases. Increasing demand for these kits is due to quick diagnosis and fast results obtained through them, which reduces the diagnostic time involved, expediting the treatment process. In addition, they diagnose chest pain and help identify risk factors prior to the occurrence of adverse cardiac events.

Order your copy of the Free Sample of “Biomarkers Industry Data Book - Cardiac Biomarkers, Cancer Biomarkers, Non-alcoholic Steatohepatitis Biomarkers, Neurological Biomarkers Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

Neurological Biomarkers Market Type Outlook, Key Takeaways

Neurological Biomarkers Market Insights

The global neurological biomarkers market size was valued at USD 6.85 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 12.8% from 2022 to 2030. Technological advancements, a rising prevalence of neurological disorders such as Parkinson's disease, Alzheimer's Disease (AD), dementia, brain tumors, & epilepsy, and increased funding for R&D of neurological biomarkers are factors responsible for market growth over the forecast period.

The COVID-19 pandemic brought both opportunities and challenges in the market for neurological biomarkers. While there was a growing demand for biomarkers due to the virus's neurological implications, hurdles such as disruptions in research and development activities, delayed clinical trials, and economic constraints disrupted market expansion. These challenges can hinder market growth by impeding the timely introduction of new neurological biomarkers, affecting their overall adoption and market penetration.

An increasing prevalence of neurological disorders is anticipated to drive market advancement. As per WHO estimates, in the U.S., stroke is the third leading cause of death and Parkinson’s disease currently impacts around 1 million people in the country. Technological advancements in biomarkers have made it easier for physicians and researchers to track & manage brain health.

Go through the table of content of Biomarkers Industry Data Book to get a better understanding of the Coverage and scope of the study

Biomarkers Industry Data Book Competitive Landscape

The market has become intensely competitive, and products must successfully clear rigorous assessments, which puts them at a significant clinical advantage over existing products. However, existing brands are constantly renovating and improvising their products to maintain their market position. Consequently, new entrants must demonstrate improved performance in terms of safety, efficiency, precision, accuracy, speed, and user convenience. In addition, aggressive marketing and promotion of the products are key strategies adopted by players entering the market.

Key players operating in the Biomarkers Industry are:

  • Hoffmann-La Roche Ltd.
  • Abbott
  • Epigenomics AG.
  • General Electric
  • Johnson and Johnson Services, Inc.

Check out more Industry Data Books, published by Grand View Research

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead. 

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com/sector-reports-list
Follow Us: LinkedIn | Twitter 

Biomarkers Industry Top Players are Abbott, General Electric, and F. Hoffmann-La Roche Ltd.

Biomarkers Industry Data Book - Cardiac & Cancer Biomarkers, Non-alcoholic Steatohepatitis Biomarkers, and Global Neurological Biomarkers Market Size, Share, Trends Analysis, and Segment Forecasts, 2023 - 2030

Grand View Research’s biomarkers industry data book is a collection of market sizing & forecasts insights, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analyses studies. Within the purview of the database, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research.

Access the Global Biomarkers Industry Data Book, 2023 to 2030, compiled with details like trade data, pricing intelligence, and competitive benchmarking.

Cardiac Biomarker Market Report Highlights

The global cardiac biomarkers market was valued at USD 13.98 billion in 2021 and is anticipated to witness growth at a rate of 14.7% over the forecast period.

  • By type, the troponin segment held the largest revenue share in 2021 owing to its high usage in cardiovascular diseases diagnosis
  • Based on application, the acute coronary syndrome segment is expected to grow at a lucrative rate during the forecast period due to the increasing prevalence of coronary diseases and expanding applications of these biomarkers in the diagnosis and treatment of diseases
  • North America dominated the global market in 2021 owing to the presence of a developed healthcare system that facilitates easier adoption of cardiac biomarkers as a tool for diagnosis and prognosis
  • Asia Pacific is expected to grow at a significant rate during the forecast period. This can be attributed to the presence of a wide target population and leading companies that are making R&D investments in countries such as China and Japan

Cardiac Biomarkers Market Share, by End use, 2021 (%)

Non-alcoholic Steatohepatitis Biomarkers Market Report Highlights

The global NASH biomarkers market was valued at USD 800.6 million in 2021 and is anticipated to witness growth at a rate of 23.6% over the forecast period.

  • By type, the serum biomarkers segment held a larger share of the NASH biomarkers market since serum biomarkers are most effective and most widely used diagnosis tool
  • By end-use, the pharma & CRO industry segment is expected to show the fastest growth over the forecast period due to the high demand for non-invasive tools for the diagnosis of liver diseases
  • North America dominated the global market in 2022, owing to the rising prevalence of infectious diseases, cardiovascular diseases, and cancer
  • Key players operating in the market are focusing on collaborations and partnerships focusing on expanding the awareness about early diagnosis and presence of diagnostic tools for determining NAFLD and NASH

Order your copy of Free Sample of “Biomarkers Industry Data Book - Cardiac & Cancer Biomarkers, Non-alcoholic Steatohepatitis Biomarkers, and Global Neurological Biomarkers Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

Cancer Biomarkers Market Report Highlights

The global cancer biomarkers market was valued at USD 19.9 billion in 2021 and is anticipated to witness growth at a rate of 13.9% over the forecast period.

  • Breast cancer was the largest segment by revenue share in 2016 owing to high prevalence of this type of cancer
  • Lung cancer is estimated to be the fastest-growing type due to increasing research activities toward development of novel lung cancer biomarkers
  • Genetic biomarkers, being the highest used and easily detectable held the majority share of cancer biomarker market by biomolecule in 2016
  • However, epigenetic biomarkers are anticipated to witness lucrative growth due to increasing focus on finding the role of epigenetic modifications in cancer development
  • Cancer biomarkers are majorly used for diagnostic purpose owing to their high specificity

Neurological Biomarkers Market Type Outlook, Key Takeaways

Neurological Biomarkers Market Report Highlights

The global neurological biomarkers market was valued at USD 6.85 billion in 2021 and is anticipated to witness growth at a rate of 12.8% over the forecast period.

  • Increasing collaborations and public-private partnerships for research initiatives may fuel market growth
  • In 2020, the proteomic biomarkers segment accounted for the largest market share and is anticipated to maintain its dominance over the forecast period
  • The Parkinson’s disease segment led the market in 2020. An increasing number of clinical trials for Parkinson’s disease drugs and the growing prevalence of the disease is expected to drive the segment growth in the years to come
  • North America was the largest regional market in 2020 owing to the high disease burden, acceptance of biomarkers for diagnostic, prognostics, & drug development purposes, and increase in research funding
  • Asia Pacific is anticipated to witness the fastest CAGR over the forecast period owing to a rising number of clinical trials being conducted in developing countries, such as India and China, increasing disease burden, and growing need for targeted drugs in the central nervous system

Go through the table of content of Biomarkers Industry Data Book to get a better understanding of the Coverage & Scope of the study

Competitive Landscape

The market has become intensely competitive, and products must successfully clear rigorous assessments, which puts them at a significant clinical advantage over existing products. However, existing brands are constantly renovating and improvising their products to maintain their market position. Consequently, new entrants must demonstrate improved performance in terms of safety, efficiency, precision, accuracy, speed, and user convenience. In addition, aggressive marketing and promotion of the products are key strategies adopted by players entering the market.

Key players operating in the Biomarkers industry are:

  • Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Bio-Rad Laboratories
  • Epigenomics AG
  • Thermo Fisher Scientific, Inc.

Check out more Industry Data Books, published by Grand View Research

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead. 

Contact:  

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com/sector-reports-list
Follow Us: LinkedIn | Twitter

Urban Growth and Electricity Demand Expand the Footprint of the Protective Relay Market

Protective relays rarely make headlines, but power systems depend on them. They detect faults, isolate the affected section in milliseconds,...